Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes

키워드

참고문헌 (99)

1. Prasad-Reddy L, "A clinical review of GLP- 1 receptor agonists: efficacy and safety in diabetes and beyond", Drugs Context, 4, pp.212283~ (2015)
2. Inzucchi SE, "Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", Diabetologia, 55, pp.1577~1596 (2012)
3. Garber AJ, "AACE comprehensive diabetes management algorithm 2013", Endocr Pract, 19, pp.327~336 (2013)
4. Baggio LL, "Biology of incretins: GLP-1 and GIP", Gastroenterology, 132, pp.2131~2157 (2007)
5. Drucker DJ, "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, openlabel, non-inferiority study", Lancet, 372, pp.1240~1250 (2008)
6. Buse JB, "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6)", Lancet, 374, pp.39~47 (2009)
7. Villanueva-Peñacarrillo ML, "Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models", Endocrine, 15, pp.241~248 (2001)
8. Holst JJ, "Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut", FEBS Lett, 211, pp.169~174 (1987)
9. Tian L, "Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor", Endocrinology, 151, pp.3049~3060 (2010)
10. Sano H, "Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic β-cell destruction induced by encephalomyocarditis virus", Biochem Biophys Res Commun, 404, pp.756~761 (2011)
11. Li L, "Glucagonlike peptide-1 protects beta cells from cytokineinduced apoptosis and necrosis: role of protein kinase B", Diabetologia, 48, pp.1339~1349 (2005)
12. Lee YS, "Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells", Metabolism, 63, pp.9~19 (2014)
13. Holst JJ, "Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes", Diabetes Care, 34(Suppl 2), pp.S251~S257 (2011)
14. Holst JJ, "Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans", Am J Physiol Endocrinol Metab, 287, pp.E199~E206 (2004)
15. Hui H, "Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes", Diabetes Metab Res Rev, 21, pp.313~331 (2005)
16. Suzuki S, "Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas", Endocrinology, 125, pp.3109~3114 (1989)
17. Orskov C, "Tissue and plasma concentrations of amidated and glycineextended glucagon-like peptide I in humans", Diabetes, 43, pp.535~539 (1994)
18. Gupta V, "Glucagon-like peptide-1 analogues: an overview", Indian J Endocrinol Metab, 17, pp.413~421 (2013)
19. Neumann JM, "Class-B GPCR activation: is ligand helixcapping the key", Trends Biochem Sci, 33, pp.314~319 (2008)
20. Widmann C, "Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas", Biochem J, 310(Pt 1), pp.203~214 (1995)
21. Runge S, "Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity", Br J Pharmacol, 138, pp.787~794 (2003)
22. Wilmen A, "Five out of six tryptophan residues in the N-terminal extracellular domain of the rat GLP-1 receptor are essential for its ability to bind GLP-1", Peptides, 18, pp.301~305 (1997)
23. López de Maturana R, "The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP- 1 requires polarity at Asp198 rather than negative charge", FEBS Lett, 530, pp.244~248 (2002)
24. Thorens B, "Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor", Diabetes, 42, pp.1678~1682 (1993)
25. Wilmen A, "The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity", FEBS Lett, 398, pp.43~47 (1996)
26. López de Maturana R, "Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues", Protein Pept Lett, 11, pp.15~22 (2004)
27. Al-Sabah S, "The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists", FEBS Lett, 553, pp.342~346 (2003)
28. Beinborn M, "A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness", Regul Pept, 130, pp.1~6 (2005)
29. Garber AJ, "Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability", Diabetes Care, 34(Suppl 2), pp.S279~S284 (2011)
30. Nauck MA, "Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients", Diabetologia, 36, pp.741~744 (1993)
31. Farilla L, "Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats", Endocrinology, 143, pp.4397~4408 (2002)
32. Imeryüz N, "Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms", Am J Physiol, 273(4 Pt 1), pp.G920~G927 (1997)
33. Wettergren A, "Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow", Am J Physiol, 275(5 Pt 1), pp.G984~G992 (1998)
34. Ruan HB, "O-GlcNAc transferase enables AgRP neurons to suppress browning of white fat", Cell, 159, pp.306~317 (2014)
35. Amato A, "Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors", Neurogastroenterol Motil, 22, pp.664-e203~ (2010)
36. Wettergren A, "The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation", Gut, 40, pp.597~601 (1997)
37. Gülpinar MA, "Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats", Am J Physiol Gastrointest Liver Physiol, 278, pp.G924~G929 (2000)
38. Ayachi SE, "Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39)", Neurogastroenterol Motil, 17, pp.302~309 (2005)
39. Nakade Y, "Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats", Auton Neurosci, 131, pp.50~56 (2007)
40. Law NM, "Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans", Am J Physiol Gastrointest Liver Physiol, 281, pp.G1228~G1237 (2001)
41. Zhao S, "Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner", Int J Obes (Lond), 36, pp.1522~1528 (2012)
42. Hayes MR, "Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema is required for energy balance regulation", Cell Metab, 11, pp.77~83 (2010)
43. Larsen PJ, "Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem", Neuroscience, 77, pp.257~270 (1997)
44. Baggio LL, "Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight", J Clin Invest, 124, pp.4223~4226 (2014)
45. Sisley S, "Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect", J Clin Invest, 124, pp.2456~2463 (2014)
46. Secher A, "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss", J Clin Invest, 124, pp.4473~4488 (2014)
47. Morton GJ, "The NPY", AgRP neuron and energy homeostasis, 2001, pp.25(Suppl 5), S56~S62
48. Sapru HN, "Role of the hypothalamic arcuate nucleus in cardiovascular regulation", Auton Neurosci, 175, pp.38~50 (2013)
49. Doyle ME, "Mechanisms of action of glucagon-like peptide 1 in the pancreas", Pharmacol Ther, 113, pp.546~549 (2007)
50. Holst JJ, "The physiology of glucagon-like peptide 1", Physiol Rev, 87, pp.1409~1439 (2007)
51. Renström E, "Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells", J Physiol, 502(Pt 1), pp.105~118 (1997)
52. Shibasaki T, "Essential role of Epac2", Rap1 signaling in regulation of insulin granule dynamics by cAMP, 2007, pp.104, 19333~19338
53. Wang Y, "Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046- 38 cells", Endocrinology, 136, pp.4910~4917 (1995)
54. Vilsbøll T, "The effects of glucagon-like peptide-1 on the beta cell", Diabetes Obes Metab, 11(Suppl 3), pp.11~18 (2009)
55. Dunning BE, "Alpha cell function in health and disease: influence of glucagon-like peptide-1", Diabetologia, 48, pp.1700~1713 (2005)
56. Zander M, "Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study", Lancet, 359, pp.824~830 (2002)
57. Lockie SH, "Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling", Diabetes, 61, pp.2753~2762 (2012)
58. López M, "Hypothalamic GLP-1: the control of BAT thermogenesis and browning of white fat", Adipocyte, 4, pp.141~145 (2015)
59. Shimizu I, "Identification and localization of glucagon-like peptide-1 and its receptor in rat brain", Endocrinology, 121, pp.1076~1082 (1987)
60. Cano G, "Anatomical substrates for the central control of sympathetic outflow to interscapular adipose tissue during cold exposure", J Comp Neurol, 460, pp.303~326 (2003)
61. Uno T, "Role of inferior olive and thoracic IML neurons in nonshivering thermogenesis in rats", Am J Physiol Regul Integr Comp Physiol, 280, pp.R536~R546 (2001)
62. Kim KW, "Steroidogenic factor 1 directs programs regulating dietinduced thermogenesis and leptin action in the ventral medial hypothalamic nucleus", Proc Natl Acad Sci U S A, 108, pp.10673~10678 (2011)
63. Jo YH, "Endogenous BDNF regulates inhibitory synaptic transmission in the ventromedial nucleus of the hypothalamus", J Neurophysiol, 107, pp.42~49 (2012)
64. López M, "Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance", Nat Med, 16, pp.1001~1008 (2010)
65. Martínez de Morentin PB, "Estradiol regulates brown adipose tissue thermogenesis via hypothalamic AMPK", Cell Metab, 20, pp.41~53 (2014)
66. Ramadori G, "SIRT1 deacetylase in POMC neurons is required for homeostatic defenses against dietinduced obesity", Cell Metab, 12, pp.78~87 (2010)
67. Mentlein R, "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum", Eur J Biochem, 214, pp.829~835 (1993)
68. Plamboeck A, "Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig", Diabetologia, 48, pp.1882~1890 (2005)
69. Mentlein R, "Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides", Regul Pept, 85, pp.9~24 (1999)
70. Hansen L, "Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine", Endocrinology, 140, pp.5356~5363 (1999)
71. Gee NS, "An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues", Biochem J, 228, pp.119~126 (1985)
72. Eng J, "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas", J Biol Chem, 267, pp.7402~7405 (1992)
73. Kim W, "The role of incretins in glucose homeostasis and diabetes treatment", Pharmacol Rev, 60, pp.470~512 (2008)
74. Kolterman OG, "Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus", Am J Health Syst Pharm, 62, pp.173~181 (2005)
75. Egan JM, "The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes", J Clin Endocrinol Metab, 87, pp.1282~1290 (2002)
76. Kolterman OG, "Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes", J Clin Endocrinol Metab, 88, pp.3082~3089 (2003)
77. DeFronzo RA, "Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes", Diabetes Care, 28, pp.1092~1100 (2005)
78. DeFronzo RA, "Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study", Curr Med Res Opin, 24, pp.2943~2952 (2008)
79. Buse JB, "Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study", Lancet, 381, pp.117~124 (2013)
80. Diamant M, "Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial", Lancet, 375, pp.2234~2243 (2010)
81. Drucker DJ, "Enhancing incretin action for the treatment of type 2 diabetes", Diabetes Care, 26, pp.2929~2940 (2003)
82. Mentis N, "GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes", Diabetes, 60, pp.1270~1276 (2011)
83. Dharmalingam M, "Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus", Indian J Endocrinol Metab, 15, pp.9~17 (2011)
84. Chang AM, "The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose", Diabetes, 52, pp.1786~1791 (2003)
85. Russell-Jones D, "Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial", Diabetologia, 52, pp.2046~2055 (2009)
86. Fala L, "Tanzeum (Albiglutide): a once-weekly GLP-1 receptor agonist subcutaneous injection approved for the treatment of patients with type 2 diabetes", Am Health Drug Benefits, 8(Spec Feature), pp.126~130 (2015)
87. Bush MA, "Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects", Diabetes Obes Metab, 11, pp.498~505 (2009)
88. Weissman PN, "HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea", Diabetologia, 57, pp.2475~2484 (2014)
89. Pratley RE, "Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study", Lancet Diabetes Endocrinol, 2, pp.289~297 (2014)
90. Woodward HN, "Once-weekly albiglutide in the management of type 2 diabetes: patient considerations", Patient Prefer Adherence, 8, pp.789~803 (2014)
91. Barrington P, "A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes", Diabetes Obes Metab, 13, pp.426~433 (2011)
92. Fala L, "Trulicity (Dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes", Am Health Drug Benefits, 8(Spec Feature), pp.131~134 (2015)
93. Wysham C, "Erratum. efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)", Diabetes Care, 37, pp.2159~2167 (2014)
94. Giorgino F, "Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)", Diabetes Care, 38, pp.2241~2249 (2015)
95. Umpierrez G, "Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)", Diabetes Care, 37, pp.2168~2176 (2014)
96. Dungan KM, "Once-weekly dulaglutide versus oncedaily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial", Lancet, 384, pp.1349~1357 (2014)
97. Kothare PA, "Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus", J Clin Pharmacol, 48, pp.1389~1399 (2008)
98. St Onge EL, "Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes", Expert Opin Biol Ther, 10, pp.801~806 (2010)
99. Smith LL, "Dulaglutide (Trulicity): The Third Once-Weekly GLP- 1 Agonist", P T, 41, pp.357~360 (2016)

관련 논문AI추천